Life sciences Company specializing on advancing psychedelic therapeutics Cybin Inc. (OTCMKTS: CLXPF) announced sponsorship of a Kernel flow study technology to determine Ketamine’s psychedelic effect on cerebral cortex hemodynamics.
Kernel flow technology uses pulsed light instead of continuous wave light to increase measured brain information. Unlike the case with electroencephalography (EEG) electrodes which normally require gel on the head or functional magnetic resonance imaging (fMRI) studies that require a participant to lie in a scanner, the flow device, an easily wearable helmet which in the future could be widely used for neuroscientific or physiological studies of brain activity during psychedelic use.
Up to today, direct neuroimaging research of psychedelic effects in living organisms has rarely been tried and never with a wearable device.
“We still have much to learn about what is occurring in the brain during a psychedelic experience. This first-of-its-kind, Cybin-sponsored study, using the Kernel Flow device, aims to expand our physiological understanding of psychedelic pharmacotherapy. We are excited to be part of this pioneering journey with our partners at Kernel,” said the company’s CEO, Doug Drysdale.
